Published in Scand J Haematol on January 01, 1974
Bleeding in renal failure: a possible cause. Br Med J (1976) 2.82
Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet (1985) 1.66
Factor VIII related antigen in the assessment of vasculitis. Ann Rheum Dis (1987) 1.43
The effects of epinephrine infusion in patients with von Willebrand's disease. J Clin Invest (1976) 0.94
Bleeding in renal failure: is von Willebrand factor implicated? Br Med J (1977) 0.91
Erosive hemorrhagic gastroduodenitis with fibrinolysis and low factor XIII. Ann Surg (1975) 0.84
Letter: Fetal puerperal septicaemia. Br Med J (1974) 0.75
What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer (1987) 6.20
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med (1995) 5.85
Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA (1998) 4.65
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA (1992) 4.31
The relation between survival and age at diagnosis in breast cancer. N Engl J Med (1986) 4.21
Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med (1980) 4.03
Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA (1997) 3.80
Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. Uppsala-Orebro Breast Cancer Study Group. J Natl Cancer Inst (1994) 2.81
Molecular pathology of haemophilia B. EMBO J (1989) 2.74
Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst (1996) 2.71
10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol (1999) 2.64
The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst (1996) 2.57
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost (2006) 2.56
Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol (1997) 2.46
The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology (1997) 2.29
Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol (1998) 2.09
Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer. Eur J Surg Oncol (2002) 2.09
Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial. Eur J Cancer (2006) 2.09
Significant reduction in advanced breast cancer. Results of the first seven years of mammography screening in Kopparberg, Sweden. Diagn Imaging Clin Med (1985) 2.02
[Problems of interpretation in vascular surgery]. Lakartidningen (1993) 1.94
Thromboembolic disease--critical evaluation of laboratory investigation. Thromb Haemost (1992) 1.93
Fibrinolytic activity of human veins. Lancet (1967) 1.91
Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med (1998) 1.91
Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst (2001) 1.90
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (2006) 1.84
Increasing survival trend after cancer diagnosis in Sweden: 1960-1984. J Natl Cancer Inst (1989) 1.82
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost (2008) 1.81
Defective fibrinolysis in blood and vein walls in recurrent "idiopathic" venous thrombosis. Acta Chir Scand (1972) 1.74
Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology (1992) 1.65
The incidence and distribution of CpG----TpG transitions in the coagulation factor IX gene. A fresh look at CpG mutational hotspots. Nucleic Acids Res (1990) 1.64
Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) (1980) 1.64
Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med (1999) 1.61
A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res (1980) 1.59
Mammographic screening for breast cancer. What cancers do we find? Eur J Cancer (1997) 1.58
Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol (2002) 1.58
No association between fat and fatty acids intake and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2001) 1.56
Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Lancet (1990) 1.53
Intrauterine death and circulating anticoagulant ("antithromboplastin"). Acta Med Scand (1975) 1.51
A nascent secretory protein may traverse the ribosome/endoplasmic reticulum translocase complex as an extended chain. J Biol Chem (1996) 1.51
Risk factors for local recurrence after conservative treatment in stage I breast cancer. Definition of a subgroup not requiring radiotherapy. Ann Oncol (1997) 1.51
Body weight and colorectal cancer risk in a cohort of Swedish women: relation varies by age and cancer site. Br J Cancer (2001) 1.49
Florence statement on breast cancer, 1998 forging the way ahead for more research on and better care in breast cancer. Eur J Cancer (1999) 1.48
Determination of plasminogen in clots and thrombi. Thromb Diath Haemorrh (1966) 1.48
Coagulation and fibrinolytic studies during pregnancy. Acta Obstet Gynecol Scand (1967) 1.48
Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol (1975) 1.47
Haemophilia prophylaxis in Sweden. Acta Paediatr Scand (1976) 1.46
The effect of female sex hormones on cancer survival. A register-based study in patients younger than 20 years at diagnosis. JAMA (1990) 1.45
Screening for osteopenia and osteoporosis: selection by body composition. Osteoporos Int (1996) 1.45
Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med (1997) 1.44
Intravascular coagulation and acute renal failure in a child with mycoplasma infection. Acta Med Scand (1971) 1.44
Pulmonary reactions to nitrofurantoin. 447 cases reported to the Swedish Adverse Drug Reaction Committee 1966-1976. Eur J Respir Dis (1981) 1.43
Risk factors for male breast cancer--a case-control study from Scandinavia. Acta Oncol (2001) 1.40
[Threatened future of plasma products. Who is responsible?]. Lakartidningen (1996) 1.39
Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer (2001) 1.33
Purification of urokinase by affinity chromatography. Biochim Biophys Acta (1976) 1.32
Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. Eur J Cancer (2003) 1.31
The dual role of interferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis. Immunology (1998) 1.30
Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol (1965) 1.29
Two genetic variants of von Willebrand's disease. N Engl J Med (1973) 1.25
Completeness of case ascertainment and survival time error in English cancer registries: impact on 1-year survival estimates. Br J Cancer (2011) 1.24
Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet (2000) 1.23
Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC). J Clin Invest (1982) 1.23
[Risk of thromboembolism with oral contraceptives]. Lakartidningen (1967) 1.23
A prospective study of association of monounsaturated fat and other types of fat with risk of breast cancer. Arch Intern Med (1998) 1.22
Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res Ed) (1985) 1.19
Smoking, antioxidant vitamins, and the risk of hip fracture. J Bone Miner Res (1999) 1.19
Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. N Engl J Med (1983) 1.18
Alcoholism and cancer risk: a population-based cohort study. Cancer Causes Control (1992) 1.17
Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature (1976) 1.17
Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat (1996) 1.16
Demands on surgical inpatient services after mass mammographic screening. Br Med J (Clin Res Ed) (1986) 1.15
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost (2006) 1.14
Coagulation and fibrinolytic studies during use of gestagens. Acta Obstet Gynecol Scand (1967) 1.14
Catheter material and blood coagulation studies in vitro. Scand J Haematol (1969) 1.13
Fibrinolysis in newborns. Acta Paediatr Scand (1970) 1.12
Nurse-led follow-up on demand or by a physician after breast cancer surgery: a randomised study. Eur J Oncol Nurs (2004) 1.12
Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia (2002) 1.11
New aspects of the pathogenesis of thrombo-embolism. Prog Surg (1973) 1.11
Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol (1997) 1.10
Maternal and infantile infection with Chlamydia in a Swedish population. Acta Paediatr Scand (1981) 1.10
The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res (2001) 1.10
Fibrin degradation products and ovarian tumours. Br Med J (1971) 1.08
Thrombolytic effect of streptokinase as evaluated by phlebography of deep venous thrombi of the leg. Acta Chir Scand (1970) 1.08
Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort. Int J Cancer (2010) 1.08
Risk factors for local recurrence after breast-conserving surgery. Br J Surg (2003) 1.08
Thrombosis and oral contraceptives: possible predisposition. Br Med J (1973) 1.07
Protein C activity and antigen in premature and fullterm newborn infants. Acta Paediatr Scand (1989) 1.07
Coagulation and fibrinolytic studies during continuous use of low dose gestagen. Acta Endocrinol (Copenh) (1970) 1.07
Long-term survival in 406 males with breast cancer. Br J Cancer (1985) 1.07
European guidelines for quality assurance in the surgical management of mammographically detected lesions. European Breast Cancer Working Group. Ann Chir Gynaecol (1998) 1.07
Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol (1976) 1.06
Shelf-life of bank blood and stored plasma with special reference to coagulation factors. Transfusion (1983) 1.06
Hereditary X-linked thrombocytopenia maps to the same chromosomal region as the Wiskott-Aldrich syndrome. Blood (1988) 1.06
Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int (2006) 1.06